Cargando…
The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study
INTRODUCTION: Current guidelines for relapsing-remitting multiple sclerosis (RRMS) call for treatment with disease-modifying therapies (DMTs) early in the disease to prevent relapses and accumulation of neurologic impairment and disability. However, patients taking certain oral DMTs may experience g...
Autores principales: | Jivraj, Farah, Kang, Sha, Reedie, Scott, Kapadia, Shivani, Strzok, Sara, Elliott, Emma, Cano, Stefan, Rock, Marvin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438375/ https://www.ncbi.nlm.nih.gov/pubmed/36053450 http://dx.doi.org/10.1007/s12325-022-02250-x |
Ejemplares similares
-
Disclosure of Adverse Events: A Guide for Clinicians
por: Peterson, Kimberly A., et al.
Publicado: (2019) -
Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies
por: Dillon, Alexander B., et al.
Publicado: (2015) -
The Role of Selected Serpins in Gastrointestinal (GI) Malignancies
por: Pączek, Sara, et al.
Publicado: (2022) -
Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021) -
Stay (GI) Healthy: COVID-19 and Gastrointestinal Manifestations
por: Vespa, Edoardo, et al.
Publicado: (2021)